Effective cabergoline treatment in idiopathic restless legs syndrome

Neurology

Volumn 63, Issue 12, 2004, Pages 2272-2279

  Stiasny Kolster, Karin ^a,j   Benes, H ^b   Peglau, I ^c   Hornyak, M ^d   Holinka, B ^e   Wessel, K ^f   Emser, W ^g   Leroux, M ^h   Kohnen, R ⁱ   Oertel, W H ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b Clinic of Neurology   (Germany)

^c University Hospital ^*

^d UNIVERSITY OF FREIBURG   (Germany)

^e RUHR UNIVERSITY BOCHUM   (Germany)

^f TECHNICAL UNIVERSITY OF BRAUNSCHWEIG   (Germany)

^g Pharmacia GmbH   (Germany)

^h Pharmacia GmbH   (Germany)

ⁱ IMEREM   (Germany)

^j Center of Nervous Diseases   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PLACEBO;

ADULT; AGED; ARTICLE; CHRONIC DRUG ADMINISTRATION; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE EXACERBATION; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHEMA; FATIGUE; FEMALE; HALLUCINATION; HEADACHE; HUMAN; IDIOPATHIC DISEASE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NERVOUSNESS; NIGHT; OUTCOMES RESEARCH; PARESTHESIA; PATIENT SATISFACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; REMISSION; RESTLESS LEGS SYNDROME; SCORING SYSTEM; SIDE EFFECT; SLEEP PATTERN; SYMPTOM; THORAX PAIN; VISUAL IMPAIRMENT; VOMITING; WEIGHT GAIN;

EID: 19944396765     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000147297.51023.C8     Document Type: Article

References (24)

1. Allen R, Picchietti D, Hening W, et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institute of Health. Sleep Med 2003;4:101-119.
2. Littner MR, Kushida C, Anderson M, et al. Practice parameters for the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder. Sleep 2004;27:557-559.
3. Hening WA, Allen RR, Earley CJ, Picchietti DL, Silber MH. An update on the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder. Sleep 2004;27:560-583.
4. Stiasny K, Roebbecke J, Schüler P, Oertel WH. Treatment of idiopathic restless legs syndrome (RLS) with the D2-agonist cabergoline-an open clinical trial. Sleep 2000;23:349-354.
5. Walters AS. Toward a better definition of the restless legs syndrome. The International Restless Legs Syndrome Study Group. Mov Disord 1995;10:634-642.
6. Kohnen R, Oertel WH, Stiasny-Kolster K, Benes H, Trenkwalder C. Severity rating of Restless Legs Syndrome: review of ten years experience with the RLS-6 scales in clinical trials. Sleep 2003;26:A342.
7. The International Restless Legs Syndrome Study Group. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs. Sleep Med 2003;4:121-132.
8. Fariello RG. Pharmacodynamic and pharmacokinetic features of cabergoline. Drugs 1997;55:10-16.
9. Ahlskog JE, Muenter MD, Adler CH. Adjunctive cabergoline therapy of Parkinson's disease: comparison with placebo and assessment of dose responses and duration of effect. Clin Neuropharmacol 1996;19:202-212.
10. Marco AD, Appiah-Kubi LS, Chaudhuri KR. Use of the dopamine agonist cabergoline in the treatment of movement disorders. Expert Opin Pharmacother 2002;3:1481-1487.
11. Porter MC, Appiah-Kubi LS, Chaudhuri KR. Treatment of Parkinson's disease and restless legs syndrome with cabergoline, a long-acting dopamine agonist. Int J Clin Pract 2002;56:468-474.
12. Trenkwalder C, Stiasny K, Pollmächer T, et al. L-dopa therapy of uremic and idiopathic restless legs syndrome: a double-blind, crossover trial. Sleep 1995;18:681-688.
13. Collado-Seidel V, Kazenwadel J, Wetter TC, et al. A controlled study of additional SR-L-dopa in L-dopa responsive RLS with late night symptoms. Neurology 1999;52:285-290.
14. Allen RP, Earley CJ. Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep 1996;19:205-213.
15. Earley CJ, Allen RP. Pergolide and carbidopa/levodopa treatment of the restless legs syndrome and periodic leg movements in sleep in a consecutive series of patients. Sleep 1996;19:801-810.
16. Silber MH, Shepard JW, Jr., Wisbey JA. Pergolide in the management of restless legs syndrome: an extended study. Sleep 1997;20:878-882.
17. Stiasny K, Wetter TC, Winkelmann J, et al. Long-term effects of pergolide in the treatment of restless legs syndrome. Neurology 2001;56: 1399-1402.
18. Ferini-Strambi L, Oldani A, Castronovo V, Zucconi M. RLS augmentation and pramipexole long-term treatment. Neurology 2001;56(8 Suppl 3):A20.
19. Stiasny-Kolster K, Oertel WH. Low-dose pramipexole in the management of restless legs syndrome-an open label trial. Neuropsychobiology 2004;50:65-70.
20. Winkelmann JW, Bennet S. Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome. Sleep Med 2004; 5:9-14.
21. Benes H, Heinrich CR, Ueberall MA, Kohnen R. Long-term safety and efficacy of cabergoline for the treatment of idiopathic restless legs syndrome: results from an open-label 6-month clinical trial. Sleep 2004;27: 674-682.
22. Zucconi M, Oldani A, Castronovo V, Ferini-Strambi L. Cabergoline is an effective single-drug treatment for restless legs syndrome: clinical and actigraphic evaluation. Sleep 2003;26:815-818.
23. Wetter TC, Stiasny K, Winkelmann J, et al. A randomized controlled study of pergolide in patients with restless legs syndrome. Neurology 1999;52:944-950.
24. Trenkwalder C, Hundemer HP, Lledo A, et al., on behalf of the PEARLS Study Group. A randomized long-term placebo-controlled multicenter trial of pergolide in the treatment of restless legs syndrome with central evaluation of polysomnographic data. Neurology 2004;62: 1391-1397.